AI is secret weapon for cancer trial recruitment and engagement, says TrialJectory CEO

AI is secret weapon for cancer trial recruitment and engagement, says TrialJectory CEO

Artificial intelligence can remove barriers to participation, aid patient engagement and boost enrollment rates in cancer trials, according to an analysis by tech firm TrialJectory.

TrialJectory shared the research in a poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting this week, explaining that its AI-based approach had outperformed traditional methods.

Specificity is the key benefit of AI, according to CEO Tzvia Bader, who told FierceCRO that complicated and confusing medical jargon and eligibility criteria, as well as difficulties connecting with trial sites, make it hard for patients to participate in studies.

To try to address this, TrialJectory uses AI to match cancer patients with the right clinical trials for their exact diagnosis, Bader said.

“TrialJectory’s AI platform discovers all available and relevant trials in a way that individual doctors cannot do on their own,” the CEO said, adding that the technology uses machine learning and natural language processing to structure massive quantities of unstructured clinical trial protocols.

“Our AI engine also identifies barriers within a clinical trial’s design and operations,” Bader added. “These actionable insights are shared with pharma to accelerate the overall clinical trials program.”

The system integrates real-world data from other patients with similar medical profiles, treatments and treatment outcomes, enabling oncologists to accurately inform prospective patients about their treatment options.

The platform currently has details of over 65,000 cancer patients, with around 4,000 new members signing up each month. The firm claims it has already made over 1 million clinical trial matches to date and says that 25% of patients currently in the database are enrolled in trials.

The ASCO poster presentation is in keeping with growing patient desire for involvement in treatment decisions, Bader said.

“We’ve seen a paradigm shift amongst cancer patients who, now more than ever, want to take control of their treatment journey and partake in clinical trials,” the CEO added. “Our poster highlights this important issue and how TrialJectory was designed to solve it, with the patient at the forefront of our mission.”


error: Content is protected !!